NCT05773092View on ClinicalTrials.gov

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions
NSCLC
Interventions
DRUG

Oral S-1 + Oral Osimertinib

S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.

Trial Locations (1)

169690

National Cancer Center Singapore, Singapore

All Listed Sponsors
collaborator

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

lead

National Cancer Centre, Singapore

OTHER